Twinbeech Capital LP Sells 27,962 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Twinbeech Capital LP decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 27.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 74,101 shares of the medical research company’s stock after selling 27,962 shares during the quarter. Twinbeech Capital LP’s holdings in IQVIA were worth $14,562,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter worth approximately $33,000. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA during the fourth quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA during the fourth quarter worth approximately $60,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.4%

Shares of IQV stock opened at $143.32 on Tuesday. The stock’s fifty day moving average price is $158.99 and its two-hundred day moving average price is $185.26. The company has a market cap of $24.79 billion, a PE ratio of 19.11, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the business posted $2.54 EPS. IQVIA’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on IQV shares. Barclays lowered their target price on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Mizuho lowered their target price on IQVIA from $210.00 to $190.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. JPMorgan Chase & Co. lowered their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a research note on Monday. Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Finally, Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $228.14.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.